Pharma & Human Health
Oragenics, Inc. and Texas A&M University System Granted U.S. Patent for Lantibiotic MU1140
Oragenics, Inc. (NYSE American: OGEN) (the “Company”), a clinical stage biotechnology company, today announced that the United States Patent and Trademark Office (USPTO) has granted Oragenics and The Texas A&M University System U.S. Patent No. […]